Bacterial and clinical characteristics of health care-and community-acquired bloodstream infections due to pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3969-3975

  Hattemer, Angela ^a,b   Hauser, Alan ^c   Diaz, Maureen ^d   Scheetz, Marc ^c   Shah, Nirav ^e   Allen, Jonathan P ^c   Porhomayon, Jahan ^a,b   El Solh, Ali A ^a,b  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED BLOODSTREAM INFECTION; FEMALE; HEALTH CARE ASSOCIATED BLOODSTREAM INFECTION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL SECRETION SYSTEMS; COMMUNITY-ACQUIRED INFECTIONS; CONFIDENCE INTERVALS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84880283125     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02467-12     Document Type: Article

References (46)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
2. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. 2003. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37:745-751.
3. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gramnegative bacilli. Clin. Infect. Dis. 41:848-854.
4. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. 2005. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49:1306-1311.
5. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. 2005. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb. Drug Resist. 11:68-74.
6. Lodise TP, Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. 2007. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 51:3510-3515.
7. Hauser AR, Cobb E, Bodi M, Mariscal D, Vallés J, Engel JN, Rello J. 2002. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 30:521-528.
8. Sadikot RT, Blackwell TS, Christman JW, Prince AS. 2005. Pathogenhost interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 171:1209-1223.
9. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13:560-578.
10. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 19:419-426.
11. Bisbe J, Gatell JM, Puig J, Mallolas J, Martinez JA, Jimenez de Anta MT, Soriano E. 1988. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev. Infect. Dis. 10:629-635.
12. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. 2000. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch. Intern. Med. 160:501-509.
13. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. 1989. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87:540-546.
14. Mallolas J, Gatell JM, Miro JM, Marco F, Soriano E. 1990. Epidemiologic characteristics and factors influencing the outcome of Pseudomonas aeruginosa bacteremia. Rev. Infect. Dis. 12:718-719.
15. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137:791-797.
16. Vallés J, Calbo E, Anoro E, Fontanals D, Xercavins M, Espejo E, Serrate G, Freixas N, Morera MA, Font B, Bella F, Segura F, Garau J. 2008. Bloodstream infections in adults: importance of healthcare-associated infections. J. Infect. 56:27-34.
17. Kollef MH, Zilberberg MD, Shorr AF, Vo L, Schein J, Micek ST, Kim M. 2011. Epidemiology, microbiology and outcomes of healthcareassociated and community-acquired bacteremia: a multicenter cohort study. J. Infect. 62:130-135.
18. Son JS, Song JH, Ko KS, Yeom JS, Ki HK, Kim SW, Chang HH, Ryu SY, Kim YS, Jung SI, Shin SY, Oh HB, Lee YS, Chung DR, Lee NY, Peck KR. 2010. Bloodstream infections and clinical significance of healthcareassociated bacteremia: a multicenter surveillance study in Korean hospitals. J. Korean Med. Sci. 25:992-998.
19. Scheetz MH, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, Sriram P, Dinh M, Owens LK, Hauser AR. 2009. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn. Microbiol. Infect. Dis. 64:311-319.
20. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. 2012. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit. Care Med. 40:1157-1163.
21. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. 1998. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on sepsisrelated problems of the European Society of Intensive Care Medicine. Crit. Care Med. 26:1793-1800.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
23. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36:309-332.
24. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, P. A.
25. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K. 2008. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 178:513-519.
26. Nicas TI, Iglewski BH. 1984. Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S. Infect. Immun. 45:470-474.
27. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
28. Hauser AR, Kang PJ, Engel JN. 1998. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence. Mol. Microbiol. 27:807-818.
29. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.
30. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54:3717-3722.
31. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daures JP, Sotto A. 2004. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J. Hosp. Infect. 57:209-216.
32. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, Gatell JM, Soriano E, Jimenez de Anta MT. 1996. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch. Intern. Med. 156:2121-2126.
33. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. 1998. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int. J. Infect. Dis. 2:211-215.
34. Blot S, Vandewoude K, Hoste E, Colardyn F. 2003. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. J. Hosp. Infect. 53:18-24.
35. Vallés J, Alvarez-Lerma F, Palomar M, Blanco A, Escoresca A, Armestar F, Sirvent JM, Balasini C, Zaragoza R, Marin M, Study Group of Infectious Diseases of the Spanish Society of Critical Care Medicine. 2011. Health-care-associated bloodstream infections at admission to the ICU. Chest 139:810-815.
36. Tsay RW, Siu LK, Fung CP, Chang FY. 2002. Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch. Intern. Med. 162:1021-1027.
37. Peña C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodriguez-Bano J, Rodriguez F, Tubau F, Martinez-Martinez L, Oliver A, Spanish Network for Research in Infectious Diseases Research. 2012. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob. Agents Chemother. 56:1265-1272.
38. Schechner V, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Finkelstein R, Lachish T, Wiener-Well Y, Alon D, Chowers M, Bardenstein R, Zimhony O, Paz A, Potasman I, Giladi M, Schwaber MJ, Klarfeld-Lidji S, Hochman M, Marchaim D, Carmeli Y. 2011. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagn. Microbiol. Infect. Dis. 71: 38-45.
39. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. 2006. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27:893-900.
40. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38:670-677.
41. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48.
42. Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, Nanas S, Paniara O, Roussos C, Giamarellos-Bourboulis E, Routsi C, Zakynthinos SG. 2007. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med. 33: 1524-1532.
43. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. 2003. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47:2756-2764.
44. van Delden C. 2007. Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int. J. Antimicrob. Agents 30(Suppl 1):S71-S75.
45. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31: 2742-2751.
46. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP. 2001. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J. Infect. Dis. 183:1767-1774.